Cyclosporine before PCI in patients with acute myocardial infarction

New England Journal of Medicine

Volumn 373, Issue 11, 2015, Pages 1021-1031

  Cung, Thien Tri ^a   Morel, Olivier ^c   Cayla, Guillaume ^d   Rioufol, Gilles ^e,f   Garcia Dorado, David ^ap   Angoulvant, Denis ^k   Bonnefoy Cudraz, Eric ^e,f   Guérin, Patrice ^m   Elbaz, Meier ⁿ   Delarche, Nicolas ^o   Coste, Pierre ^p   Vanzetto, Gerald ^q   Metge, Marc ^r   Aupetit, Jean Francois ^g   Jouve, Bernard ^s   Motreff, Pascal ^t   Tron, Christophe ^u   Labeque, Jean Noel ^v   Steg, Philippe Gabriel ^w   Cottin, Yves ^x   Range, Grégoire ^y   Clerc, Jérome ^z   Claeys, Marc J ^aq   Coussement, Patrick ^ar   Prunier, Fabrice ^aa   Moulin, Frédéric ^ab   Roth, Olivier ^ac   Belle, Loïc ^ae   Dubois, Philippe ^as   Barragan, Paul ^af   Gilard, Martine ^ag   Piot, Christophe ^b   Colin, Patrice ^ah   De Poli, Fabien ^ah   Morice, Marie Claude ^ai   Ider, Omar ^ad   Dubois Rande, Jean Luc ^aj   Unterseeh, Thierry ^ak   Le Breton, Hervé ^al   Béard, Thierry ^am   Blanchard, Didier ^l   Grollier, Gilles ^an   Malquarti, Vincent ^h   Staat, Patrick ⁱ   Sudre, Arnaud ^ao   Elmer, Eskil ^at   Hansson, Magnus J ^at   Bergerot, Cyrille ^e,f,j   Boussaha, Inesse ^e,f,j   Jossan, Claire ^e,f,j   Derumeaux, Geneviève ^e,f,j   Mewton, Nathan ^e,f,j   Ovize, Michel ^e,f,j   more..

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b Clinique du Millenaire   (France)

^c HÔPITAL CIVIL   (France)

^d NÎMES UNIVERSITY HOSPITAL   (France)

^e Hôpital Cardiovasculaire Louis Pradel   (France)

^f UNIVERSITÉ LYON 1   (France)

^g Centre Hospitalier Saint Joseph et Saint Luc   (France)

^h Lyon Ortho Clinic   (France)

ⁱ Clinique du Tonkin   (France)

^j Inserm   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l Clinique Saint Gatien   (France)

^m CHU de Nantes   (France)

ⁿ CHU RANGUEIL   (France)

^o CENTRE HOSPITALIER DE PAU   (France)

^p HAUT LÉVÊQUE HOSPITAL   (France)

^q GRENOBLE UNIVERSITY HOSPITAL   (France)

^r Hôpital Henri Duffau   (France)

^s CENTRE HOSPITALIER DU PAYS D AIX   (France)

^t SERVICE DE RHUMATOLOGIE   (France)

^u HÔPITAL CHARLES NICOLLE   (France)

^v Clinique de la Fourcade   (France)

^w BICHAT HOSPITAL   (France)

^x HÔPITAL DU BOCAGE   (France)

^y Centre Hospitalier General   (France)

^z Centre Hospitalier Compiegne   (France)

^aa ANGERS UNIVERSITY HOSPITAL   (France)

^ab CHU NANCY BRABOIS   (France)

^ac CHU de Mulhouse   (France)

^ad Clinique du sport   (France)

^ae Centre Hospitalier de la Region d'Annecy   (France)

^af Polyclinique des Fleurs   (France)

^ag SERVICE DE RHUMATOLOGIE   (France)

^ah Clinique Esquirol   (France)

^ai Institut Jacques Cartier   (France)

^aj HENRI MONDOR HOSPITAL   (France)

^ak Hôpital Claude Galien   (France)

^al PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^am Clinique de l'Ormeau   (France)

^an CHU CÔTE DE NACRE   (France)

^ao LILLE UNIVERSITY HOSPITAL   (France)

^ap HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^aq ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^ar General Hospital St Jan   (Belgium)

^as Centre Hospitalier Universitaire de Charleroi   (Belgium)

^at LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CYCLOSPORIN; PLACEBO; CYCLOPHILIN; ENZYME INHIBITOR; PPID PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BARE METAL STENT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY RECANALIZATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBUS ASPIRATION; UNSTABLE ANGINA PECTORIS; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MYOCARDIAL INFARCTION; PHASE 3 CLINICAL TRIAL;

AGED; COMBINED MODALITY THERAPY; CYCLOPHILINS; CYCLOSPORINE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; HEART FAILURE; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; VENTRICULAR REMODELING;

EID: 84941308478     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1505489     Document Type: Article

References (33)

1. Puymirat E, Aissaoui N, Cottin Y, et al. Effect of coronary thrombus aspiration during primary percutaneous coronary intervention on one-year survival (from the FAST-MI 2010 registry). Am J Cardiol 2014; 114: 1651-7.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35.
3. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015; 65: 1454-71.
4. Ibanez B, Macaya C, Sánchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation 2013; 128: 1495-503.
5. Khan AR, Binabdulhak AA, Alastal Y, et al. Cardioprotective role of ischemic postconditioning in acute myocardial infarction: a systematic review and metaanalysis. Am Heart J 2014; 168: 512-21.
6. Crompton M, Costi A. A heart mitochondrial Ca2(+)-dependent pore of possible relevance to re-perfusion-induced injury: evidence that ADP facilitates pore interconversion between the closed and open states. Biochem J 1990; 266: 33-9.
7. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995; 307: 93-8.
8. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434: 658-62.
9. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434: 652-8.
10. Duchen MR, McGuinness O, Brown LA, Crompton M. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 1993; 27: 1790-4.
11. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-81.
12. Mewton N, Cung TT, Morel O, et al. Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial). Am Heart J 2015; 169(6): 758.e6-766.e6.
13. Ehinger KH, Hansson MJ, Sjövall F, Elmér E. Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor EL. Clin Drug Investig 2013; 33: 25-34.
14. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.
15. Savoye C, Equine O, Tricot O, et al. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol 2006; 98: 1144-9.
16. Ortiz-Pérez JT, Meyers SN, Lee DC, et al. Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J 2007; 28: 1750-8.
17. Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010; 87: 406-23.
18. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014; 66: 1142-74.
19. Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 2015; 372: 1389-98.
20. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012; 307: 1817-26.
21. Cohen MV, Downey JM. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J Cardiovasc Pharmacol Ther 2014; 19: 179-90.
22. Li J, Iorga A, Sharma S, et al. Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A. Anesthesiology 2012; 117: 836-46.
23. Sanchez H, Zoll J, Bigard X, et al. Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain. Br J Pharmacol 2001; 133: 781-8.
24. Zalewski J, Claus P, Bogaert J, et al. Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion. Basic Res Cardiol 2015; 110: 18
25. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010; 24: 85-7.
26. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55: 534-43.
27. Chiari P, Angoulvant D, Mewton N, et al. Cyclosporine protects the heart during aortic valve surgery. Anesthesiology 2014; 121: 232-8.
28. Hausenloy Dj, Kunst G, Boston-Griffiths E, et al. The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. Heart 2014; 100: 544-9.
29. Lim WY, Messow CM, Berry C. Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis. Br J Pharmacol 2012; 165: 2034-43.
30. Ghaffari S, Kazemi B, Toluey M, Sepehrvand N. The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. Cardiovasc Ther 2013; 31(4): e34-e39.
31. De Paulis D, Chiari P, Teixeira G, et al. Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart. Basic Res Cardiol 2013; 108: 379.
32. Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA. The Global Registry of Acute Coronary Events, 1999 to 2009 - GRACE. Heart 2010; 96: 1095-101.
33. Garcia-Dorado D, García-del-Blanco B, Otaegui I, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol 2014; 177: 935-41.